A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1487-1491

  Paolicchi, Elisa ^a   Pacetti, Paola ^b   Giovannetti, Elisa ^c   Mambrini, Andrea ^b   Orlandi, Massimo ^b   Crea, Francesco ^a   Romani, Antonello A ^d   Tartarini, Roberta ^b   Danesi, Romano ^a   Peters, Godefridus J ^c   Cantore, Maurizio ^b  

^a UNIVERSITY OF PISA   (Italy)

^b Carrara Civic Hospital   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

Cholangiocarcinoma; ECX regimen; EZH2; Polycomb; Polymorphism

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; COMPUTER MODEL; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84884481851     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1559     Document Type: Article

References (37)

1. Parkin DM, Ohshima H, Srivatanakul P and Vatanasapt V: Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev 2: 537-544, 1993.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA and McGlynn KA: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 5: 1221-1228, 2007.
4. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ and Hassan MM: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 102: 1016-1021, 2007.
5. Albores-Saavedra J, Murakata L, Krueger JE and Henson DE: Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts. Cancer 89: 508-515, 2000.
6. Farges O and Fuks D: Clinical presentation and management of intrahepatic cholangiocarcinoma. Gastroenterol Clin Biol 34: 191-199, 2010.
7. Lim JH and Park CK: Pathology of cholangiocarcinoma. Abdom Imaging 29: 540-547, 2004.
8. Gatto M and Alvaro D: New insights on cholangiocarcinoma. World J Gastrointest Oncol 2: 136-145, 2010.
9. Leelawat K, Narong S, Wannaprasert J and Ratanashu-ek T: Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol 16: 4697-4703, 2010.
10. Seehofer D, Kamphues C and Neuhaus P: Management of bile duct tumors. Expert Opin Pharmacother 9: 2843-2856, 2008.
11. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med 341: 1368-1378, 1999.
12. Valk-Lingbeek ME, Bruggeman SW and van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell 118: 409-418, 2004.
13. Lund AH and van Lohuizen M: Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16: 239-246, 2004.
14. Mathews LA, Crea F and Farrar WL: Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 78: 1-17, 2009.
15. Liu DC and Yang ZL: Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 207: 472-478, 2011.
16. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
17. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003.
18. Jacobs JJ, Kieboom K, Marino S, DePinho RA and vanLohuizenM: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168, 1999.
19. Sasaki M, Yamaguchi J, Itatsu K, Ikeda H and Nakanuma Y: Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol 215: 175-183, 2008.
20. Yoon KA, Gil HJ, Han J, Park J and Lee JS: Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J Thorac Oncol 5: 10-16, 2010.
21. Messeguer X, Escudero R, Farré D, Núñez O, Martinez J and Albà MM: PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18: 333-334, 2002.
22. Farré D, Roset R, Huerta M, Adsuara JE, Rosello L, Albà MM and Messeguer X: Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res 31: 3651-3653, 2003.
23. Barenboim M, Zoltick BJ, Guo Y and Weinberger DR: MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets. Hum Mutat 31: 1223-1232, 2010.
24. Rodriguez S, Gaunt TR and Day IN: Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169: 505-514, 2009.
25. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH and Gores GJ: Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 122: 985-993, 2002.
26. Kim EM, Kim JS, Choi MH, Hong ST and Bae YM: Effects of excretory/secretory products from Clonorchis sinensis and the carcinogen dimethylnitrosamine on the proliferation and cell cycle modulation of human epithelial HEK293T cells. Korean J Parasitol 46: 127-132, 2008.
27. Zheng T, Wang J, Chen X, Meng X, Song X, Lu Z, Jiang H and Liu L: Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. Tumour Biol 31: 287-295, 2010.
28. Han C, Lim K, Xu L, Li G and Wu T: Regulation of Wnt/beta-catenin pathway by cPLA2alpha and PPARdelta. J Cell Biochem 105: 534-545, 2008.
29. Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
30. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
31. Youssef J and Badr M: Enhanced hepatocarcinogenicity due to agonists of peroxisome prolifer-atoractivated receptors in senescent rats: role of peroxisome proliferation, cell proliferation and apoptosis. ScientificWorldJournal 2: 1491-1500, 2002.
32. Kliewer SA, Umesono K, Noonan DJ, Heyman RA and EvansRM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774, 1992.
33. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheatWL and Green S: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11: 433-439, 1992.
34. Chase A and Cross NC: Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618, 2011.
35. Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, IkedaH, Nimura Y, Nagino M and Nakanuma Y: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 101: 355-362, 2010.
36. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, Minato H, Ohta T and Nakanuma Y: The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882, 2008.
37. Nakanuma Y, Sasaki M, Sato Y, Ren X, Ikeda H and HaradaK: Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World J Hepatol 1: 35-42, 2009.